Antimicrobial resistance (AMR) is a global health challenge with an estimated 67% increase in global deaths attributable to AMR by 2050. The European Partnership One Health AMR (EUP OHAMR) is aiming to reduce the burden of AMR with an integrated One Health (OH) approach, recognising that human, animal and plant health are interdependent and interlinked with the environment. The partnership will boost AMR research and innovation (R&I) addressing the current knowledge gaps with the aim to improve surveillance of resistant pathogens and provide better diagnostics and more effective treatments of drug-resistant infections. It will support implementation research on prevention measures reducing the use of antimicrobials and spread of AMR and launch an ambitious work programme of joint activities to coordinate R&I investments, facilitate the use and re-use of R&I data, strengthen AMR R&I capacities and facilitate both knowledge translation and uptake of research results and innovations by industry, society, and policy makers. The EUP OHAMR builds on the long-standing collaboration of the partners from the Joint Programme Initiative on AMR (JPIAMR) but with a bigger ambition and a broader scope. The partnership consists of 53 partners from 30 countries from the European Union (EU) and beyond. With active engagement of key stakeholders across the AMR landscape, the partnership will strengthen European and global synergies through alignment of research priorities, policies, and investments. Furthermore, EUP OHAMR will support multisectoral and multidisciplinary collaborations to break the existing silos in AMR research. It will result in increased knowledge and solutions and provide an evidence base for uptake into policy and practice to prevent and tackle AMR. Thus, the EUP OHAMR will deliver towards to the priorities set in the European One Health Action plan against AMR, thereby strengthening the European Research and Innovation Area ecosystem and contribute to making the EU a best-practice region on AMR.

The general purpose of PRECISEU is connecting innovation ecosystems across Europe to efficiently advance towards a truly personalised healthcare, transferring practices and solutions from region to region and scaling up deep-tech healthcare innovations based on advanced therapies medicinal products and health data across Europe. The PRECISEU consortium is composed of Regional Authorities and innovation players from 9 NUTS 1 and 2 regions, supported by clusters, universities, research centres and infrastructures, NGOs and networks, and engaging regional and European innovators, scientists and entrepreneurs across the EU health innovation space. Also involved as partner in the consortium, one Ukrainian Region, Rivne, represented by the Rivne Medical Cluster, has a relevant role as Ukraine is open for cooperation, innovation and joint projects for reconstruction. The European continent faces a set of challenges in terms of the swift and effective implementation of medical care, which were brought sharply into focus during the COVID-19 pandemic. Healthcare remains a concurrent gap between innovation leaders and emerging and moderate innovators (classification according to the Regional Innovation Scoreboard, RIS), which impacts all spheres (economics, social and living standards), and which requires significant expertise and knowledge as well as expansive collaboration between innovation networks and all stakeholders and communities across Europe. PRECISEU is aware that taking next steps in the development and organisation of PM is a key issue for Europe, and that more coordination efforts between key European stakeholders is necessary to foster its implementation. By focusing on health data and advanced therapies as key drivers of personalized medicine models, PRECISEU will not only provide regional ecosystems with European connectivity but will most importantly address the significant and urgent needs of the regions.

Smart Health is EU Strategic Value Chain that contributes to growth, jobs and competitiveness. Health Data is the main enabler for the value chain, but it also depends on cutting edge technologies - AI, cloud computing, IoT, to integrate the dispersed knowledge and support innovative healthcare solutions and services. EC sets the creation of a European Health Data Space as a main priority, to promote better exchange and access to health data. On a regional level, the RIS3 strategies of the involved widening countries - Bulgaria, Romania, Greece and Cyprus emphasize the need for based on Big Data, AI and IoT digitalized healthcare, to enable personalized medicine, informed decisions, and improved disease prediction. RIS3 strategies also outline the need for more funding for R&I, policy coherence and development of territorially join innovation strategies. A cross country coordinated approach is needed to align the separate endeavours towards an Excellent South-East Europe Smart Health Innovation Ecosystem enabled by a Regional Smart Health Data Space. VELES raises the level of innovation excellence in the South-East EU through creating a sustainable place-based innovation ecosystem, enabled by Regional Smart Health Data Space, including novel transformational framework, R&I and investment strategy and action plan for research, development and adoption of innovative and secure digital solutions that underpin the delivery of sustainable healthcare services. The Regional Smart Health Data Space will be demonstrated through the design of 4 interrelated pilots on Cancer treatment (Greece); Personalised/precision medicine of Alzheimer (Bulgaria); Cerebral tumours (Romania) and Dementia (Cyprus). The aim of VELES is to foster health data sharing regional and national strategies, to secure improved clinical practice, to preserve patient’s privacy and to empower citizens’ smart healthcare through access to innovative, cyber secure and data driven digital health services.

Non-communicable diseases (NCDs) account for 80% of the disease burden as well as for the majority of premature deaths in the EU; diminishing the citizens’ quality of life, life expectancy and increasing the financial burden (from those affected to the health system). During the last 3 decade environmental stressors have been addressed through numerous studies, which have raised concerns about the detrimental effects of the environment on human health. Most evaluated environmental stressors are air temperature, particulate and gaseous air pollutants, urban noise, food pollutants and radiation. By end of 2022, air pollution was reported to be responsible of an excess mortality of 311.000 people per year in the UE-27 , driving not only premature deaths but also an increased risk of vascular diseases such as ischemic heart disease, stroke, and other non-communicable non-vascular diseases like chronic respiratory diseases or depression. Some newly considered stressors such as electromagnetic field, and light exposure are also susceptible to affect human health (e.g ocular and dermatological NCD diseases). ENACT aims at building a pathway to generate clinical, technological and economic short & long-term impact targeting local and regional stakeholders and create impact by: Developing a state-of-the-art environmental risk score and analyser driven framework and platform to predict, monitor and prevent the exposomic risk of acute and chronic health conditions of chronic vascular and non-vascular NCDs. This new exposomic risk score and analyser will support (a) patients, (b) health professionals/hospitals, and (c) policy makers; aiming at reducing the human and financial burden of NCD, considering potential individual vulnerability factors, and reinforcing both a clinical and a policy implementation that enables prevention and disease management for higher quality of life.

INNAXE aims at strengthening the interconnection and fostering the dialog among European Life Sciences and Healthtech innovation ecosystems, to increase their efficiency and innovation capacities, with the focus on the twin transformation that ecosystems’ stakeholders are already experiencing. INNAXE intends to define and prepare a joint actionable plan towards more interconnected, inclusive, sustainable, dynamic and competitive Life Sciences and Healthcare innovation ecosystems across the EU and Associated countries, to overcome the current fragmentation when it comes to innovation capabilities. The consortium is composed of 6 leading cluster organisations that bring together, connect, coordinate, dynamise, and accelerate the Life Sciences and Healthtech innovation ecosystems’ community at regional level in Catalonia (Biocat, ES), Île de France (Medicen, FR), Rhine-Neckar (BioRN, DE); at national level in Bulgaria (HLSC, BG) and Denmark (DLSC, DK) and at EU level and Associated Countries (CEBR, BE). The regional/national ecosystems in this consortium cover all the innovation levels of the European Innovation Scoreboard (EIS) and Regional Innovation Scoreboard (RIS) , from emerging innovators to innovation leaders. The Joint Action Plan will specifically address performance gaps of emerging and moderate innovator regions, with the help of strong innovator and innovation leader regions. The project will broaden its scope to include ecosystems from other EU and Associated countries through the Council of European BioRegions (CEBR), a partner in this project. INNAXE intends to align the project outcomes to the diverse policies in the EU agenda for innovation, EC Work Programs, and regional, local and national agendas, as well as other EU-funded projects, exploring complementarities and synergies to draft an optimal Joint Action Plan (JAP).